- Conditions
- Melanoma
- Interventions
- Dietary Intervention, Questionnaire Administration
- Dietary Supplement · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1201–1224
of 2,669
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Placebo, GC33
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Bethesda, Maryland • Detroit, Michigan + 4 more
- Conditions
- Hepatocellular Carcinoma, Pancreas Cancer, Biliary Tract Neoplasms
- Interventions
- Actigraphy, Online Mindfulness Meditation, Smartphone Application-based Intervention, Survey Administration
- Other · Behavioral
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Asthma
- Interventions
- MRx-4DP0004, Placebo
- Drug
- Lead sponsor
- 4D pharma plc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Atypical Facial Pain, Persistent Idiopathic Facial Pain, Atypical Trigeminal Neuralgia, Neuropathic Orofacial Pain, Neuropathic Facial Pain
- Interventions
- ATNC05, Placebo
- Drug
- Lead sponsor
- Allodynic Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 89 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- North Miami, Florida
- Conditions
- Iron Deficiency Anemia
- Interventions
- Ferric Carboxymaltose (FCM), Iron Sucrose / Iron Dextran
- Drug
- Lead sponsor
- American Regent, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Norristown, Pennsylvania
- Conditions
- Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Interventions
- RO7965032, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 5
- States / cities
- Walnut Creek, California • Winston-Salem, North Carolina • Erie, Pennsylvania + 2 more
- Conditions
- Visual Acuity
- Interventions
- senofilcon A Multifocal, senofilcon A Sphere, etafilcon A Multifocal, etafilcon A Sphere
- Device
- Lead sponsor
- Johnson & Johnson Vision Care, Inc.
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 6
- States / cities
- Whittier, California • Jacksonville, Florida • Maitland, Florida + 3 more
- Conditions
- HIV, HIV-1, Human Immunodeficiency Virus
- Interventions
- GS-9137 - A Novel HIV-1 Integrase Inhibitor
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 278 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 49 more
- Conditions
- Other Fatty Acid Oxidation Disorders, Diabetes Mellitus, Insulin Resistance
- Interventions
- Lipid/heparin
- Other
- Lead sponsor
- Temple University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Childbirth
- Interventions
- Materna Prep Device, Sham Control
- Device
- Lead sponsor
- Materna Medical
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Mountain View, California
- Conditions
- Atrial Fibrillation, Esophageal Carcinoma
- Interventions
- Amiodarone Hydrochloride, Saline
- Drug · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Healthy Volunteers
- Interventions
- Sucralose, Aspartame, Acesulfame-Potassium, Control
- Other
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 6 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasm
- Interventions
- CHAMPS-II adapted to adults 60+ years in HCT setting
- Behavioral
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Heart Failure
- Interventions
- IASD System II implant, intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
- Device · Other
- Lead sponsor
- Corvia Medical
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 36 more
- Conditions
- Prostate Cancer
- Interventions
- soy isoflavones, neoadjuvant therapy, Placebo
- Dietary Supplement · Procedure · Other
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2010
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Prostate Cancer
- Interventions
- Investigators choice of SoC, AAA817
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 443 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 35
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 30 more
- Conditions
- Head and Neck Squamous Cell Carcinoma, Cancer, Cancer of Head and Neck, Cancer, Advanced, Cancer, Metastatic, Tumor, Tumor Recurrence, Tumor Neck, Tumor Metastasis, Oral Cancer, Oropharyngeal Cancer, Oropharynx Cancer, Oropharynx Cancer, Stage III, Oropharynx Cancer, Recurrent, Oropharynx Cancer, Metastatic
- Interventions
- Pembrolizumab, Radiation therapy, Cisplatin
- Drug · Radiation
- Lead sponsor
- Loren Mell, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 6
- States / cities
- Tucson, Arizona • La Jolla, California • Tampa, Florida + 3 more
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Synovial Sarcoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Fallopian Tube Carcinoma, Metastatic Melanoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Metastatic Synovial Sarcoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Unresectable Melanoma, Unresectable Ovarian Carcinoma, Unresectable Synovial Sarcoma
- Interventions
- Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis, Leukapheresis, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
- Drug · Other · Procedure + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2032
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Spinal Cord Injuries
- Interventions
- Physical exam and medical history, Assessments, Patient Instruction and use of Device (RePlay)
- Other · Diagnostic Test · Device
- Lead sponsor
- The University of Texas at Dallas
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Addison, Texas • Richardson, Texas
- Conditions
- Asthma
- Interventions
- Daclizumab
- Drug
- Lead sponsor
- Facet Biotech
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 18
- States / cities
- Long Beach, California • Mission Viejo, California • San Diego, California + 14 more
- Conditions
- Sickle Cell Anemia, Thalassemia
- Interventions
- L-glutamine, Placebo
- Drug
- Lead sponsor
- Emmaus Medical, Inc.
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 5
- States / cities
- Bellflower, California • Torrance, California • Atlanta, Georgia + 2 more
- Conditions
- Glioblastoma Multiforme, Adult
- Interventions
- Berubicin, Lomustine
- Drug
- Lead sponsor
- CNS Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 32
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Orange, California + 28 more
- Conditions
- Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
- Interventions
- 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin, Atezolizumab, Cobimetinib, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Cisplatin, Tiragolumab
- Drug · Biological
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 3 more